The purpose of this study was to determine the acetylator status in @entity195 ( @entity195 ) @entity1 and compare it to a matched group of normal individuals. Thirty-seven healthy volunteers and forty-one @entity195 @entity1 were included. Detailed history was taken from the @entity1 . HLA-B51 was determined in the @entity195 @entity1 . In addition, the Clinical Manifestation Index (C.M.I.) was determined for each @entity1 . Pathergy test was also done. After an overnight fast, each control subject and @entity1 received a single oral dose of 100 mg of @entity15353 . A blood sample was collected after 3 hours and the plasma was separated for determination of @entity3761 / @entity6156 by HPLC. The frequency of slow acetylators in healthy individuals was 70.2%, while the frequency of rapid acetylators was 29.8%. The frequency of slow acetylators in @entity195 @entity1 was 53.7%, while the frequency of non-acetylators (undetected @entity6156 MADDS in plasma) was 46.3%. There were no rapid acetylators among the @entity195 @entity1 . There was a strong negative association between the acetylator status and the severity of @entity195 . In addition, acetylator status correlated with HLA-B51, in that @entity195 @entity1 with positive HLA-B51 were characterized by a very slow or non-acetylator status. Slow or non-acetylators had more severe @entity195 . We conclude that @entity195 @entity1 have a unique acetylator status. This finding may have implications for the theories for the pathogenesis of the disease as well as for therapeutic aspects.

Acetylator phenotype in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity15353 :: ('MESH:C535808', 'Disease') :: ['DDS'] @entity3761 :: ('MESH:D003622', 'Chemical') :: ['dapsone'] @entity6156 :: ('MESH:C018965', 'Chemical') :: ['monoacetyldapsone'] @entity195 :: ('MESH:D000544', 'Disease') :: ["Beh  et's disease", 'BD']
@entity195 :: (MESH:D000544,Disease) :: ['Beh  et's disease']
